Future MyOme Personal Genome™
and MyOme Diagnostic
Reports and Tests

Learn more about the genetic tests and reports that are coming soon or are in development for the MyOme Personal Genome™ platform. MyOme Personal Genome™ unlocks a lifetime of health information from a single sample submission, and our MyOme Genetic Tests cover a range of clinical conditions*.


Coronary Artery Disease (CAD) Integrated Risk with Polygenic Risk Score (PRS) Report

product logo CAD is the most common type of heart disease in the U.S., impacting people of all ages, with 2 in 10 deaths from CAD occurring in adults under 651. We're developing this report so everyone can check their heart health anytime.

About the Report

body graphic The report provides a single risk score that integrates genetics with clinical factors to assess risk for coronary artery disease (CAD) for those who may be missed by clinical evaluation (whereas traditional genetic panels evaluate rare genes impacting a small percent and do not assess CAD risk).

Breast Cancer Integrated Risk with Polygenic Risk Score (PRS) Report

product logo Nearly 1 in 8 women in the U.S. will develop invasive breast cancer throughout their lives2. We're developing this report to offer women on-demand access to their breast cancer risk at any age. See our publication on breast cancer risk stratification.

About the Report

body graphic If you have a family history of breast cancer but are negative for single-gene tests, including BRCA1 or BRCA2, you can still be at an elevated risk for breast cancer2. This report provides an integrated risk score that combines genetics with clinical risk factors for women without a known mutation in a breast cancer gene. This test is validated across multiple ancestries3.

MyOme Personal Genome Risk Reports In Development


Neurodevelopmental Delay (NDD) Genetic Test

product logo Despite current testing guideline recommendations for NDD, 2 out of 3 children do not receive genetic testing5,6. Current testing is complex and expensive, often leaving families without a clear diagnosis. Our test offers a comprehensive genetic testing option that streamlines the path ahead for families.

About the Report

body graphic If you believe your child has a developmental delay, this test provides an affordable genetic test option that utilizes MyOme whole genome sequencing. The test detects a wide range of changes in the genome, known as variants, which may cause developmental delay. This includes single nucleotide variants and copy number variants from as small as 10kb to single genes. Test results are delivered in weeks and may improve access to additional advanced tests if necessary.
National Center for Health Statistics. Multiple Cause of Death 2018–2021 on CDC WONDER Database. Accessed September 13, 2023.
Breast Cancer Facts and Statistics 2023, www.breastcancer.org/facts-statistics. Accessed 13 Sept. 2023.
Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol. 2015;26: 1291–1299. doi:10.1093/annonc/mdv022
Tshiaba PT, Ratman DK, Sun JM, Tunstall TS, Levy B, Shah PS, et al. Integration of a Cross-Ancestry Polygenic Model With Clinical Risk Factors Improves Breast Cancer Risk Stratification. JCO Precis Oncol. 2023;7: e2200447. doi:10.1200/PO.22.00447
Savatt JM, Myers SM. Genetic Testing in Neurodevelopmental Disorders. Front Pediatr. 2021;9: 526779. doi:10.3389/fped.2021.526779
Kiely B, Vettam S, Adesman A. Utilization of genetic testing among children with developmental disabilities in the United States. Appl Clin Genet. 2016;9: 93–100. doi:10.2147/TACG.S103975
In some cases an additional sample might be required.
footer logo

© 2024 MyOme.com

MyOme is not responsible for the content or accuracy of third-party websites

The MyOme Personal Genome™ Report was developed, and its performance characteristics were determined, by MyOme, Inc., a clinical laboratory certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform high complexity clinical laboratory testing. This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary for laboratory-developed tests.